GAIN THERAPEUTICS, INC (GANX) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $123.63K; Long-term Debt, Excluding Current MaturitiesUSD $220.06K; Long-term DebtUSD $343.69K; Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve MonthsUSD $49.45K.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $100.28K; Long-term Debt, Excluding Current MaturitiesUSD $273.26K; Long-term DebtUSD $373.55K; Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve MonthsUSD $75.21K.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $100.87K; Long-term Debt, Excluding Current MaturitiesUSD $300.08K; Long-term DebtUSD (m); Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve MonthsUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $400.95K; Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve MonthsUSD $100.87K.
GAIN THERAPEUTICS, INC Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months USD | Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two USD | Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three USD | Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four USD | Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Debt Instrument, Face Amount CHF | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Periodic Payment CHF | Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $123.63K | $220.06K | $343.69K | $49.45K | $98.90K | $98.90K | $96.43K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $100.28K | $273.26K | $373.55K | $75.21K | $100.28K | $100.28K | $97.77K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $100.87K | $300.08K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $400.95K | $100.87K | $100.87K | $100.87K | $98.35K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $125.55K | $298.80K | $424.34K | $25.11K | $100.44K | $100.44K | $100.44K | $97.92K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $126.11K | $325.36K | $451.47K | $126.11K | $100.89K | $100.89K | $100.89K | $22.70K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $113.12K | $314.48K | $427.60K | $113.12K | $90.50K | $90.50K | $90.50K | $42.98K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $110.18K | $328.33K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $438.50K | $110.18K | $88.14K | $88.14K | $88.14K | $63.90K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $118.28K | $376.13K | $494.41K | $118.28K | $94.62K | $94.62K | $94.62K | $92.26K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $111.05K | $375.35K | $486.40K | $111.05K | $88.84K | $88.84K | $88.84K | $88.84K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $19.99K |
| 2024-03-31 | $110.85K | $396.84K | $507.68K | $110.85K | $88.68K | $88.68K | $88.68K | $88.68K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $42.12K |
| 2023-12-31 | $118.80K | $449.05K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $567.85K | (m) | (m) | (m) | (m) | (m) | $118.80K | $95.04K | $95.04K | $95.04K | $95.04K | $68.90K | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $109.28K | $434.94K | $544.22K | $109.28K | $87.42K | $87.42K | $87.42K | $87.42K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $85.24K |
| 2023-06-30 | $111.64K | $466.64K | $578.27K | $111.64K | $89.31K | $89.31K | $89.31K | $89.31K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $109.40K |
| 2023-03-31 | $109.20K | $478.30K | $587.50K | $109.20K | $87.36K | $87.36K | $87.36K | $87.36K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $128.86K |
| 2022-12-31 | $108.14K | $495.26K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $603.39K | (m) | (m) | (m) | (m) | (m) | $108.14K | $86.51K | $86.51K | $86.51K | $86.51K | $149.23K | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $101.26K | $484.02K | $585.28K | $101.26K | $81.01K | $81.01K | $81.01K | $81.01K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $159.99K |
| 2022-06-30 | $83.75K | $542.26K | $626.01K | $83.75K | $83.75K | $83.75K | $83.75K | $83.75K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $207.28K |
| 2022-03-31 | $86.62K | $560.89K | $647.51K | (m) | (m) | (m) | (m) | (m) | $86.62K | $86.62K | $86.62K | $86.62K | $86.62K | $214.39K | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $103.83K | $590.47K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $694.29K | (m) | (m) | (m) | (m) | (m) | $103.83K | $87.81K | $87.81K | $87.81K | $87.81K | $239.24K | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $86.64K | $620.17K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $65.47K | $646.66K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $44.29K | $678.25K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $22.63K | $715.66K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · 20.00K | (m) |
| 2020-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 638.00K | $696.38K | 0.00% | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 14.60K | $15.93K | 0.00% | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |